InternationalUSRemember you can easily switch between MIP US and MIP International at any time

In-house IP roundup: blue-v-blue biologic litigation rises; UPC apathy after new complaint listing; businesses shed patents for cost savings



Patrick Wingrove, London


Patent Strategy, a new service from Managing IP, rounds up the latest news and analysis from patent-focused businesses

splash

Biologics market spurs blue-v-blue litigation for generics and innovators

Zentiva, Insud Pharma and an originator drug company explain how large molecule market dynamics have shifted the litigation format created by small molecule products, turning other generics and innovators into litigation targets. (Read more … ) 


UPC

UPC: businesses apathetic to 2019 complaint listing

In-house counsel explain what they’ve done so far to prepare for the Unified Patent Court, but say they’re unlikely to increase preparations, despite the complaint holding up the system’s creation being moved to this year’s agenda. (Read more … )


Abandon

Patents abandoned by companies to save and make money

Patent departments say financial constraints have compelled more businesses to abandon or sell off less valuable registrations – but they add that they are careful not to get rid of the wrong ones. (Read more … )

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.


Comments






More from the Managing IP blog


null null null

nullnullnull

null

May / June 2019

From trademarks to trade secrets: in-house tips on brand protection in China

Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies



Most read articles

Supplements